| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8962200 | Radiotherapy and Oncology | 2018 | 6 Pages |
Abstract
APBI reduces the risk of secondary cancer 2-4 fold compared to WBI. These techniques are well suited for long-living early stage breast cancer patients. HDR brachytherapy and 3D-conformal APBI achieve mean lung doses between 1 and 1.5â¯Gy, which could serve as reference.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Nienke Hoekstra, Emmanuelle Fleury, Tomas Rodrigo Merino Lara, Peter van der Baan, Andy Bahnerth, Gerson Struik, Mischa Hoogeman, Jean-Philippe Pignol,